Neoplasms, Plasma Cell: all 2,314 studies

Page 9 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.

• Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple MyelomaCompletedNCT00439465Phase 2Results posted
• Aflibercept for Relapsed Multiple MyelomaTerminatedNCT00437034Phase 2Results posted
• A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple MyelomaCompletedNCT00434161Phase 3Results posted
• Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple MyelomaCompletedNCT00432458Phase 3Results posted
• A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple MyelomaCompletedNCT00429949Phase 2Results posted
• Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple MyelomaCompletedNCT00427765Phase 2Results posted
• A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00420849Phase 3Results posted
• Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by ChemotherapyCompletedNCT00416624Phase 2Results posted
• Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple MyelomaCompletedNCT00410605Phase 2Results posted
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
• A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.CompletedNCT00405756Phase 3Results posted
• A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00401843Phase 2Results posted
• Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple MyelomaCompletedNCT00400686Not applicableResults posted
• Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for TransplantationTerminatedNCT00396383Phase 2Results posted
• AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSFCompletedNCT00396266Phase 2Results posted
• AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF AloneTerminatedNCT00395967Phase 2Results posted
• Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple MyelomaTerminatedNCT00366106Phase 2Results posted
• High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple MyelomaCompletedNCT00349778Phase 2Results posted
• Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.CompletedNCT00330759Phase 3Results posted
• Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.CompletedNCT00325416Phase 1/2Results posted
• Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma PatientsCompletedNCT00322842Phase 2Results posted
• Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma PatientsCompletedNCT00322491Phase 2Results posted
• Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma PatientsCompletedNCT00322387Phase 2Results posted
• Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesCompletedNCT00309842Phase 2Results posted
• Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell TransplantsCompletedNCT00307086Phase 2Results posted
• Allogeneic Bone Marrow Transplantation Using Less Intensive TherapyTerminatedNCT00303719Phase 2Results posted
• Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell TransplantCompletedNCT00293384Not applicableResults posted
• Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple MyelomaCompletedNCT00287872Phase 2Results posted
• Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
• Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - DenosumabCompletedNCT00259740Phase 2Results posted
• Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple MyelomaCompletedNCT00258206Phase 2Results posted
• MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous TransplantationTerminatedNCT00256776Phase 3Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic CancerTerminatedNCT00255684Not applicableResults posted
• Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00245037Phase 1/2Results posted
• PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple MyelomaTerminatedNCT00240162Phase 2Results posted
• A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple MyelomaCompletedNCT00229203Phase 2Results posted
• A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of LifeCompletedNCT00222105Phase 2Results posted
• Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple MyelomaCompletedNCT00217438Phase 3Results posted
• Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple MyelomaCompletedNCT00185614Phase 2Results posted
• Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple MyelomaCompletedNCT00179647Phase 3Results posted
• Autologous Transplant for Multiple MyelomaCompletedNCT00177047Phase 2/3Results posted
• Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage ITerminatedNCT00171925Phase 3Results posted
• Bortezomib (Velcade) in Patients With Untreated Multiple MyelomaCompletedNCT00153920Phase 2Results posted
• Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple MyelomaCompletedNCT00148317Phase 2Results posted
• Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple MyelomaCompletedNCT00135200Phase 2Results posted
• Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerCompletedNCT00134017Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00134004Phase 2Results posted
• Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00128921Phase 2Results posted
• S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00124579Phase 2Results posted
• UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma PatientsTerminatedNCT00113919Phase 1/2Results posted
• Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple MyelomaCompletedNCT00113841Not applicableResults posted
• Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00112827Phase 1/2Results posted
• Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedNCT00112723Phase 1/2Results posted
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
• Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))CompletedNCT00111813Phase 1Results posted
• A Multiple Myeloma Trial in Patients With Bone MetastasesCompletedNCT00104104Phase 4Results posted
• Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma PatientsCompletedNCT00103662Phase 3Results posted
• Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple MyelomaCompletedNCT00103506Phase 3Results posted
• Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering MyelomaCompletedNCT00099047Phase 2Results posted
• A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00097981Phase 3Results posted
• Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple MyelomaCompletedNCT00090493Phase 2/3Results posted
• Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
• Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple MyelomaCompletedNCT00084747Phase 1/2Results posted
• DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE ConsolidationCompletedNCT00083915Phase 3Results posted
• UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation ChemotherapyCompletedNCT00083551Phase 3Results posted
• Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and ThalidomideCompletedNCT00083382Phase 2Results posted
• Bortezomib in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00075881Phase 2Results posted
• Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)CompletedNCT00075829Phase 3Results posted
• 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) AmyloidosisTerminatedNCT00075608Phase 2Results posted
• S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic AmyloidosisCompletedNCT00064337Phase 2Results posted
• S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00064038Phase 3Results posted
• CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00056160Phase 3Results posted
• NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/DisordersCompletedNCT00053989Phase 2Results posted
• Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple MyelomaCompletedNCT00049673Phase 3Results posted
• Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
• S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00040937Phase 2Results posted
• Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
• Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple MyelomaCompletedNCT00006244Phase 2Results posted
• Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple MyelomaCompletedNCT00006184Phase 2Results posted
• Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple MyelomaCompletedNCT00004088Phase 2Results posted
• Antineoplaston Therapy in Treating Patients With Multiple MyelomaTerminatedNCT00003511Phase 2Results posted
• Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003270Phase 2Results posted
• Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving ChemotherapyCompletedNCT00002850Phase 3Results posted
• CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT07809594Phase 1
• CD70.CAR for CD70+ Lymphoma, Myeloma and Solid TumorsWithdrawnNCT07297160Phase 1
• A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma PatientsCompletedNCT07206810
• Feasibility, Safety and Effectivity of an Exercise Intervention for Newly Diagnosed Multiple Myeloma Patients During Induction TherapyActive, not recruitingNCT07026799Not applicable
• Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological LeukemiaActive, not recruitingNCT06944119
• Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple MyelomaActive, not recruitingNCT06924424Not applicable
• Melflufen for Elderly Patients With Relapsed MyelomaWithdrawnNCT06682637Phase 2
• The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World StudyCompletedNCT06610045
• A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care TherapiesCompletedNCT06592222
• Finistere Myeloma Observatory (OMYFIN)CompletedNCT06552221
• Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell TransplantActive, not recruitingNCT06523699Phase 1
• Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC TransplantationCompletedNCT06425276Phase 4
• A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients with Refractory and Relapsing Multiple Myeloma Expressing Somatostatin ReceptorsWithdrawnNCT06411301Phase 1
• Cohort Construction and Prognostic Model Construction for Multiple MyelomaActive, not recruitingNCT06366802
• A Real-World Study of Bispecific Antibodies in Multiple MyelomaCompletedNCT06359067
• Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMMWithdrawnNCT06352866Phase 2
• Descartes-15 for Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT06304636Phase 1

← Neoplasms, Plasma Cell overview